NTCC-inhibition with cilnidipine as an anti-SCD intervention
Cilnidipine is a "4 th -generation" Ca 2+ -channel blocker. 9 Its Kd for NTCCs is at least an order of magnitude less than that of 9 comparison Ca
2+
-channel blockers, with a higher Kd for LTCC blockade than the other agents, giving it ≥20-fold increased selectivity for NTCCs at a constant test-potential (-80 mV). 10 Studies in well-controlled animal models suggest that the drug decreases sympathetic effects on the heart, with reduced heart rate and contractility. 9 Clinical investigations have provided variable results, some compatible with reduced sympathetic outflow and others not so clear-cut. 9 In the Yamada study, cilnidipine produced dramatic protection against autonomic-tone abnormalities, VTs and death in the dnNRSF mouse CHF-model. 7 If the drug could be shown to have similar effects in human CHF patients, it could be a very valuable component of SCD-prevention in such individuals. At the very least, consideration should be by guest on November 4, 2016 given to a controlled clinical trial comparing the effects of cilnidipine to those of a more standard dihydropiridine drug like amlodipine on indices of autonomic function and ventricular ectopy in CHF patients. Positive results would motivate a larger-scale study on ventricular arrhythmias and potentially-lethal arrhythmias, perhaps beginning with a trial in high-risk subjects with implanted defibrillators.
Limitations of the study
While the Yamada study is interesting and uses several elegant models, the work has a number of significant limitations. First, there are important discrepancies between the effects of pharmacological autonomic inhibition and genetic NTCC inhibition. Cilnidipine-and bisoprololtreated mice showed reduced arrhythmias and autonomic abnormalities, but the CHF-phenotype remained unabated; whereas the CACNA1B heterozygous knockout mice demonstrated reversal of autonomic, arrhythmic and hemodynamic abnormalities. The authors note the discrepancy for cilnidipine and suggest that it may be due to adverse effects of the drug's LTCC blocking action on cardiac function, to insufficient cilnidipine doses or to a lack of central nervous system penetration of cilnidipine. 7 The authors do not comment on the discrepancy between the benefits of genetic NTCC inhibition against CHF and the lack of such benefit with bisoprolol.
Another internal inconsistency relates to the mortality rates of dnNRSF-mice in the various experimental series. Bisoprolol-treated dnNRSF-mice had a mortality-rate of about 20% at 90 days. This was significantly lower than the mortality-rate of the control dnNRSFgroup, >60% at 90 days ( Figure 3N ). However, the mortality of the latter group was unusually high, compared to virtually no mortality at 90 days (13 weeks) in the dnNRSF control group for Figure 1E ) and about a 25% death-rate for the dnNRSF/CACNA1B+/+ mice in the genetic NTCC-suppression study ( Figure 6A ). With a more typical control-group mortality, there would have been no significant difference with bisoprolol-therapy; this discrepancy requires resolution.
Another concern relates to the functional selectivity of cilnidipine in vivo. The selectivity reported for NTCCs based on in vitro studies is indeed impressive. 
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A final issue that remains to be resolved is the mechanism of death in dnNRSF-mice.
While the deaths appear to be sudden (mice found dead in their cage) and the mice clearly are prone to VTs, it remains to be clarified whether VTs are truly the cause of their premature death.
Mice are resistant to ventricular fibrillation, and even in humans Holter monitor-recorded SCD is not infrequently caused by bradyarrhythmias. 13 The authors do provide one example of a fatal VT in a nitrendipine-treated dnNRSF-mouse (Supplemental Figure 2) , but more detailed information on cardiac rhythms recorded by ambulatory monitoring at the time of death would be of interest.
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